The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...
As Súil Pharma prepares for its next phase of testing and fundraising, the company’s focus remains clear: restore sight and transform lives. The journey from a Galway startup to an award-winning ...
Johnson & Johnson entered into a definitive agreement to acquire Halda Therapeutics OpCo for $3.05 billion in cash. Eli Lilly announced it will pay $40 million upfront and up to $2.56 billion in a ...
Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ...
Chip maker Nvidia’s strong earnings and rock-solid guidance ease worries about an artificial-intelligence bubble.
The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...
Panelists discuss how key biologic and clinical distinctions—such as ischemia, leakage patterns, and modality-specific ...
Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO ...
MedPage Today on MSN
Lawsuit Over Blockbuster Med; Makary's Power Struggle; Fluoride and Better Cognition
Politico reports that Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary, MD, MPH, are at odds on how ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback